Pharmafile Logo
Pharmafocus logo
Advanced Search

oncology

Showing 15 posts of 301 posts found.

Breakthrough announced in circulating tumour cell research

June 18, 2021
Medical Communications Cancer, Circulating tumour cells, Precision Medicine, oncology

Liquid biopsy company, Angle, has announced results from their study in non-small cell lung cancer (NSCLC) which demonstrates the benefit …

News

New class of cancer-killing drugs identified

June 18, 2021
Medical Communications Cancer, oncology

Scientists have announced the identification of a new class of cancer drugs, known as POLQ inhibitors, that specifically kill cancer …

News
0000

COVID chaos: Survey reveals global oncology trial disruptions

June 10, 2021
data, oncology

The pandemic has had a widespread impact across the healthcare industry and the world, however, a recent global survey from …

News

Astronomy & cancer: Researchers join forces to study CUP

June 7, 2021
Sales and Marketing oncology

Astronomers from Durham University have joined forces with cancer researchers to advance the diagnosis and treatment of cancer of unknown …

News

BMS announce new positive data from oesophageal cancer study

June 4, 2021
Medical Communications Cancer, oncology

Bristol Myers Squibb (BMS) has announced results from the Phase III CheckMate -648 trial in which nivolumab plus chemotherapy and …

News
az

AstraZeneca’s lung cancer drug gains EU approval

May 28, 2021
Medical Communications AstraZeneca, EU, lung cancer, oncology

AstraZeneca’s Tagrisso (osimertinib) has been approved in the EU for the adjuvant treatment of adult patients with early-stage (IB, II …

News
astrazeneca_sign_sky

AstraZeneca secures MHRA licensing and NHS early access for lung cancer drug

May 7, 2021
Medical Communications Astrazenaca, oncology

AstraZeneca have announced that the MHRA has granted a license extension for Tagrisso (osimertinib) in the UK, for use as …

News

Data published on novel molecules for leukaemia treatment

April 27, 2021
Manufacturing and Production oncology

STORM Therapeutics have published new data in Nature on targeting RNA modifying enzymes for the development of new anti-cancer therapeutics, …

News
credit_-_crevis_shutterstock_340710245_720

Enhertu now available via Cancer Drugs Fund following NICE decision

April 20, 2021
Manufacturing and Production AstraZeneca, breast cancer, oncology

AstraZeneca and Daiichi Sankyo have announced that NICE has approved Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund …

News
merckwindow_web

TILT Biotherapeutics & MSD to collaborate on adenoviral cancer immunotherapy trial

April 14, 2021
Research and Development clinical trial, oncology

TILT Biotherapeutics today announced a clinical trial collaboration agreement with MSD, to evaluate TILT’s adenoviral cancer immunotherapy, TILT-123, in combination …

News

Exscientia enter first-ever AI cancer drug into Phase I trials

April 9, 2021
Medical Communications AI, Evotec, Exscientia, cancer treatment, oncology, pharma, pharma news

Exscientia and Evotec have announced that they are entering an AI-designed immuno-oncology drug into Phase I trials for the first …

News

Novartis and Artios Pharma to collaborate on DDR cancer therapies

April 7, 2021
Research and Development Novartis, RLT, oncology

Novartis and Artios Pharma have announced a global research collaboration to discover and validate next generation DNA damage response (DDR) …

News

EC approves combination treatment for kidney cancer

March 31, 2021
Research and Development Cancer, Europe, oncology

The European Commission (EC) has approved Ipsen’s Cabometyx in combination with Opdivo as a first-line treatment for advanced renal cell …

News
credit_-_daniel_leal-olivas-afp

Astellas Pharma and Seagen cancer treatment gets MAA acceptance from EMA

March 26, 2021
Medical Communications EMA, oncology

Astellas Pharma and Seagen Inc. have announced that the EMA has accepted their marketing authorisation application (MAA) for enfortumab vedotin, …

News
stock-incyte-01-shutter

Incyte biliary tract cancer treatment approved in Japan

March 23, 2021
Manufacturing and Production EMA, Japan, oncology

The Japanese Ministry of Health, Labour, and Welfare (MHLW) have approved Incyte’s Pemazyre (pemigatinib) for the treatment of patients with …

News

Latest content

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024